← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Avanti Biosciences, Inc.
East Setauket, NY
$6,728,206
Total funding
5
Grants
Funding over time
peak $1.8M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,728,206 · 5
By mechanism
SB1$3,350,753 · 1
R44$2,279,783 · 1
R43$1,097,670 · 3
Investigators at Avanti Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease$1,239,325
SB1 · FY2023 · AG
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease$1,134,429
SB1 · FY2024 · AG
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease$976,999
SB1 · FY2022 · AG
Development of DYRK1A allosteric modulator for the treatment of Alzheimerâs Disease$971,320
R44 · FY2019 · AG
Development of DYRK1A allosteric modulator for the treatment of Alzheimerâs Disease$582,601
R44 · FY2017 · AG
DYRK1A inhibitors as therapeutic approach to Tau hyper-phosphorylation for treatment of Alzheimer disease and other CNS disorders$449,436
R43 · FY2019 · AG
Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease$375,862
R44 · FY2020 · AG
Development of DYRK1A allosteric modulator for the treatment of Alzheimerâs Disease$350,000
R44 · FY2019 · AG
USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES$349,235
R43 · FY2023 · DK
Development of novel prodrugs targeting Glutamate Dehydrogenase (GDH) for the treatment of congenital hyperinsulinemia disorder including Hyperinsulinemia-Hyperammonemia Syndrome (HHS) and SCHAD-HI.$298,999
R43 · FY2018 · DK